Drug intelligence / Profile preview

Typhoid Vi conjugate vaccine

Development stage
Phase 4
Lead developer
GSK
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Intramuscular
01

Overview

Typhoid Vi conjugate vaccine is a biologic vaccine designed for the prevention of typhoid fever caused by *Salmonella enterica* serovar Typhi. It consists of the purified Vi capsular polysaccharide antigen from *S. Typhi* chemically conjugated to a carrier protein such as tetanus toxoid (Vi-TT), diphtheria toxoid (Vi-DT), or recombinant *Pseudomonas aeruginosa* exoprotein A (Vi-rEPA). The conjugation enhances immunogenicity by inducing a T-cell dependent immune response and robust anti-Vi antibody production even in young children. This results in higher efficacy and longer-lasting immunity compared to plain polysaccharide vaccines. The primary indication is active immunization against typhoid fever in children as young as 6 months and adults up to 45 years or older depending on the product[3][4][5][6][8]. Multiple companies have developed different versions using various carrier proteins.

Brand names
Typbar TCVZyvac TCVPedaTyphEuTCV
Other names
Vi-TTVi-DTVi-rEPATyphoid conjugate vaccineTCV
02

Targets

CD209 (Dendritic cell-specific intercellular adhesion Molecule-3-Grabbing non-integrin)Vi antigen (Vi capsular polysaccharide)

Beyond the preview

Go deeper on Typhoid Vi conjugate vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Typhoid Vi conjugate vaccine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call